Tags:

Cassava Sciences, Inc.


A securities class action has been filed against Cassava Sciences, Inc. (SAVA) on behalf of all persons and entities that purchased or otherwise acquired Cassava Sciences common stock between February 2, 2020 through August 24, 2021.  This case has been filed in the USDC – Texas (Western).

The Complaint alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the scientific data supporting Cassava Sciences’ claims for simulfilam’s efficacy had been overstated; (ii) the scientific data supporting Cassava Sciences’ claims for simulfilam’s efficacy were biased; and (iii) as a result, defendants’ positive statements during the Class Period about Cassava Sciences’ business metrics and financial prospects and the likelihood of U.S. Food Drug Administration (“FDA”) approval were false and misleading and/or lacked a reasonable basis.

Tags:

Securities